| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.17M | 9.32M | 13.74M | 12.50M | 6.52M |
| Gross Profit | 7.16M | 846.00K | 3.62M | 3.91M | 1.57M |
| EBITDA | 3.14M | 252.00K | 3.82M | 5.10M | 1.33M |
| Net Income | 1.24M | -903.00K | 1.66M | 2.19M | 32.00K |
Balance Sheet | |||||
| Total Assets | 38.04M | 37.74M | 39.06M | 38.36M | 34.46M |
| Cash, Cash Equivalents and Short-Term Investments | 629.00K | 163.00K | 325.00K | 1.33M | 95.00K |
| Total Debt | 1.40M | 1.99M | 2.18M | 2.54M | 3.04M |
| Total Liabilities | 2.27M | 3.36M | 3.78M | 3.37M | 6.51M |
| Stockholders Equity | 35.77M | 34.38M | 35.28M | 34.99M | 27.96M |
Cash Flow | |||||
| Free Cash Flow | 1.79M | 31.00K | 1.61M | -1.59M | -2.65M |
| Operating Cash Flow | 2.67M | 2.24M | 4.42M | 1.62M | 1.39M |
| Investing Cash Flow | -1.42M | -2.21M | -3.49M | -2.17M | -4.04M |
| Financing Cash Flow | -786.00K | -193.00K | -1.93M | 1.78M | 2.48M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | AU$58.89M | 12.85 | 3.97% | ― | 24.88% | ― | |
47 Neutral | AU$173.75M | -2.46 | -215.00% | ― | ― | ― | |
46 Neutral | AU$96.98M | -6.61 | -47.73% | ― | ― | 64.63% | |
44 Neutral | AU$32.22M | -1.90 | -12.11% | ― | ― | 23.60% | |
43 Neutral | AU$39.20M | -11.22 | -0.02% | ― | ― | -12.34% | |
41 Neutral | AU$61.38M | -2.65 | -35.91% | ― | ― | 57.49% |
Advance ZincTek Limited has released its interim financial statements for the half year ended 31 December 2025, providing shareholders and the market with updated information on its financial performance and position. The documents include the chairman’s letter, directors’ report, reviewed financial statements and auditor’s declaration, offering a formal snapshot of the company’s mid-year results and governance disclosures.
The release signals a routine but important reporting milestone that allows investors to reassess the company’s operational progress and balance sheet strength midway through the financial year. While specific performance figures are not detailed in the announcement text, the publication of the reviewed accounts and accompanying reports underlines the company’s ongoing compliance with regulatory requirements and its commitment to transparency for stakeholders.
The most recent analyst rating on (AU:ANO) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Advance ZincTek Limited stock, see the AU:ANO Stock Forecast page.
Advance ZincTek Limited has disclosed that its subsidiary ANO has been placed on a U.S. FDA Import Alert, a move the board believes may be linked to broader tariff-related issues and follows similar actions against several other Australian manufacturers over the past 18 months. In response, the company has hired U.S.-based regulatory consultants, including former FDA officials, to review its Good Manufacturing Practice systems in Brisbane, develop a corrective action plan, and file a petition within four to eight weeks to seek removal of the alert, while indicating it does not currently expect a material financial impact unless the alert remains in place through the end of the 2026 financial year and noting that a recent television report may have influenced the regulator’s decision.
The most recent analyst rating on (AU:ANO) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Advance ZincTek Limited stock, see the AU:ANO Stock Forecast page.